Fig. 1From: Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren’s syndrome: results of the BELISS studyChanges in T, B and natural killer (NK) cell counts and B-cell subtypes after belimumab therapy. *p<0.05. W weekBack to article page